Dr. Reddy’s Laboratories has entered into a landmark licensing agreement with Australian biotechnology firm Immutep to develop and commercialize a promising cancer immunotherapy candidate. The collaboration aims to accelerate clinical progress and expand global access to a next-generation treatment designed to enhance the body’s immune response against tumors. By combining Dr. Reddy’s manufacturing scale and commercialization expertise with Immutep’s scientific innovation, the partnership signals a major step in oncology research.